For patients with difficult-to-treat cancers, doctors increasingly rely on genomic testing of tumors to identify errors in the DNA that indicate a tumor can be targeted by existing therapies. But this approach overlooks rogue proteins that may be driving cancer cells and also could be targeted with existing treatments, according to research.